These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7483725)

  • 41. CYP2D6 -1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers.
    Llerena A; Dorado P; Ramírez R; Calzadilla LR; Peñas-Lledó E; Álvarez M; Naranjo ME; González I; Pérez B;
    Pharmacogenomics; 2013 Dec; 14(16):1973-7. PubMed ID: 24279852
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Relationship between amitriptyline metabolism and polymorphic debrisoquine hydroxylation in native Chinese volunteers].
    Zhang XH; Yu P; Gu NF; Yin JL; Jiang WD
    Yao Xue Xue Bao; 1993; 28(2):85-91. PubMed ID: 8328289
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine.
    Ashforth EI; Palmer JL; Bye A; Bedding A
    Br J Clin Pharmacol; 1994 Apr; 37(4):389-91. PubMed ID: 8018461
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers.
    González I; Peñas-Lledó EM; Pérez B; Dorado P; Alvarez M; LLerena A
    Pharmacogenomics; 2008 Jul; 9(7):833-40. PubMed ID: 18597648
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Kinetics of propiverine as assessed by radioreceptor assay in poor and extensive metabolizers of debrisoquine.
    Müller C; Siegmund W; Huupponen R; Kaila T; Franke G; Iisalo E; Zschiesche M
    Eur J Drug Metab Pharmacokinet; 1993; 18(3):265-72. PubMed ID: 8149945
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CYP2D6-related oxidation polymorphism in Italy.
    Spina E; Campo GM; Avenoso A; Caputi AP; Zuccaro P; Pacifici R; Gatti G; Strada G; Bartoli A; Perucca E
    Pharmacol Res; 1994 Apr; 29(3):281-9. PubMed ID: 8058599
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Altered distribution of the debrisoquine oxidative phenotypes in children with type 1 diabetes mellitus.
    Madácsy L; Barkai L; Sánta A; Krikovszky D
    Horm Res; 2004; 61(4):176-9. PubMed ID: 14726620
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Detection of debrisoquine hydroxylation phenotypes.
    Wolf CR; Moss JE; Miles JS; Gough AC; Spurr NK
    Lancet; 1990 Dec; 336(8728):1452-3. PubMed ID: 1978915
    [No Abstract]   [Full Text] [Related]  

  • 49. Genetic differences in drug disposition.
    May DG
    J Clin Pharmacol; 1994 Sep; 34(9):881-97. PubMed ID: 7983231
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lack of congruence of S-carboxymethyl-L-cysteine sulphoxidation and debrisoquine 4-hydroxylation in a Caucasian population.
    Haley CS; Waring RH; Mitchell SC; Shah RR; Idle JR; Smith RL
    Xenobiotica; 1985 May; 15(5):445-50. PubMed ID: 4036168
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6.
    Llerena A; Edman G; Cobaleda J; Benítez J; Schalling D; Bertilsson L
    Acta Psychiatr Scand; 1993 Jan; 87(1):23-8. PubMed ID: 8424321
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Acetylation phenotype in colorectal carcinoma.
    Ilett KF; David BM; Detchon P; Castleden WM; Kwa R
    Cancer Res; 1987 Mar; 47(5):1466-9. PubMed ID: 3815349
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical significance of oxidation and acetylation genetic polymorphism in patients with Parkinson's disease].
    Milejski P; Orzechowska-Juzwenko K; Kamienowski J; Horoch E; Niewiński P; Hurkacz M; Rzemisławska Z
    Neurol Neurochir Pol; 1999; 33(5):1015-24. PubMed ID: 10672554
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disposition of propafenone in a poor metabolizer of CYP2D6 with Gilbert's syndrome.
    Dilger K; Meisel P; Hofmann U; Eichelbaum M
    Ther Drug Monit; 2000 Jun; 22(3):366-8. PubMed ID: 10850406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Genetic polymorphism and metabolism of tricyclic antidepressants].
    Samyn B
    Encephale; 1992; 18(6):661-4. PubMed ID: 1342665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is debrisoquine hydroxylation modified during acute viral hepatitis?
    Joanne C; Paintaud G; Bresson-Hadni S; Magnette J; Becker MC; Miguet JP; Bechtel PR
    Fundam Clin Pharmacol; 1994; 8(1):76-9. PubMed ID: 8181799
    [TBL] [Abstract][Full Text] [Related]  

  • 57. What is Gilbert's syndrome? Lesson from genetic polymorphisms of UGT1A1 in Gilbert's syndrome from Asia.
    Kamisako T
    J Gastroenterol Hepatol; 2004 Sep; 19(9):955-7. PubMed ID: 15304109
    [No Abstract]   [Full Text] [Related]  

  • 58. [Stability and/or variability of the expression of genetic polymorphism of hydroxylation and acetylation in patients with various pathologies and under various treatments].
    Bechtel P; Joanne C; Bechtel Y; Grandmottet M; Jounet JM
    Ann Biol Clin (Paris); 1986; 44(4):361-7. PubMed ID: 3538951
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Clinically significant inherited differences in the mode of action of drugs].
    Meyer UA; Meier PJ
    Schweiz Med Wochenschr; 1982 May; 112(19):666-9. PubMed ID: 7100864
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Narcotic analgesics and debrisoquine polymorphism.
    Lavrijsen KL; Heykants JJ
    Anesthesiology; 1989 Sep; 71(3):474-5. PubMed ID: 2570539
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.